PL4153302T3 - Leczenie wirusowych zakażeń dróg oddechowych - Google Patents

Leczenie wirusowych zakażeń dróg oddechowych

Info

Publication number
PL4153302T3
PL4153302T3 PL21729598.9T PL21729598T PL4153302T3 PL 4153302 T3 PL4153302 T3 PL 4153302T3 PL 21729598 T PL21729598 T PL 21729598T PL 4153302 T3 PL4153302 T3 PL 4153302T3
Authority
PL
Poland
Prior art keywords
treatment
respiratory infections
viral respiratory
viral
infections
Prior art date
Application number
PL21729598.9T
Other languages
English (en)
Inventor
Syed Muhammad Tahir NASSER
Original Assignee
Biosirius Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosirius Ltd filed Critical Biosirius Ltd
Publication of PL4153302T3 publication Critical patent/PL4153302T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21729598.9T 2020-05-19 2021-05-19 Leczenie wirusowych zakażeń dróg oddechowych PL4153302T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2007404.3A GB202007404D0 (en) 2020-05-19 2020-05-19 Treatment for viral respiratory infections
PCT/GB2021/051207 WO2021234381A1 (en) 2020-05-19 2021-05-19 Treatment for viral respiratory infections

Publications (1)

Publication Number Publication Date
PL4153302T3 true PL4153302T3 (pl) 2024-10-07

Family

ID=71135334

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21729598.9T PL4153302T3 (pl) 2020-05-19 2021-05-19 Leczenie wirusowych zakażeń dróg oddechowych

Country Status (12)

Country Link
US (1) US20230192838A1 (pl)
EP (1) EP4153302B1 (pl)
JP (1) JP2023526853A (pl)
KR (1) KR20230053549A (pl)
CN (1) CN116406289A (pl)
AU (1) AU2021276614A1 (pl)
CA (1) CA3179461A1 (pl)
ES (1) ES2982939T3 (pl)
GB (1) GB202007404D0 (pl)
HU (1) HUE067327T2 (pl)
PL (1) PL4153302T3 (pl)
WO (1) WO2021234381A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4179328A2 (en) * 2020-07-10 2023-05-17 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US7862829B2 (en) 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
CA2822515C (en) * 2010-12-20 2023-04-25 Medimmune Limited Anti-il-18 antibodies and their uses
PT3041864T (pt) * 2013-09-05 2021-10-26 Ab2 Bio Sa Proteína de ligação a il-18 (il-18bp) em doenças inflamatórias
UA128752C2 (uk) 2015-03-05 2024-10-16 Аб2 Біо Са Фармацевтична композиція для лікування асоційованого з il-18 захворювання або порушення
WO2021224432A1 (en) * 2020-05-06 2021-11-11 Ab2 Bio Sa Il-18 binding protein (il-18bp) in respiratory diseases

Also Published As

Publication number Publication date
ES2982939T3 (es) 2024-10-21
EP4153302A1 (en) 2023-03-29
US20230192838A1 (en) 2023-06-22
EP4153302C0 (en) 2024-05-29
CN116406289A (zh) 2023-07-07
HUE067327T2 (hu) 2024-10-28
JP2023526853A (ja) 2023-06-23
AU2021276614A1 (en) 2023-01-05
KR20230053549A (ko) 2023-04-21
EP4153302B1 (en) 2024-05-29
GB202007404D0 (en) 2020-07-01
WO2021234381A1 (en) 2021-11-25
CA3179461A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
PL4157272T3 (pl) Remdesiwir do leczenia zakażeń wirusowych
ZA202006656B (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
SG11201702766YA (en) Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
GB2594617B (en) Air treatment system
GB2596086B (en) Air treatment
GB2595513B (en) Treatment of infections
IL279078A (en) Combination therapy for the treatment of hepatitis B viral infection
ZA202212662B (en) Use of compounds for treating viral infections
HUE067327T2 (hu) Vírusos légúti fertõzések kezelése
LT3471732T (lt) Liposomos, skirtos virusinių infekcijų gydymui
GB202015584D0 (en) Treatment for viral infection
EP3650015A4 (en) COMBINED DRUG PREPARATION FOR THERAPY OF VIRAL INFECTIONS
PL4021505T3 (pl) Lek do leczenia chorób zakaźnych
GB202019421D0 (en) Air treatment system
GB202006160D0 (en) Treatment of viral infections
GB202004998D0 (en) Treatment of viral infections
GB202003232D0 (en) Treatment of viral infections
GB202315114D0 (en) Viral treatment
AU2021901731A0 (en) Inhalation formulation for the treatment of respiratory viral infections
GB202105509D0 (en) Viral infections
GB202020320D0 (en) Viral infections
GB202018571D0 (en) Viral infections
GB202018446D0 (en) Viral infections
GB202013976D0 (en) Viral infections
GB202010271D0 (en) Viral infections